A Phase 1/2 Open-label Study to Investigate the Safety of Sonrotoclax Ramp-up Schedule(s) in Adult Patients With Hematological Malignancies
Latest Information Update: 08 Jun 2025
At a glance
- Drugs Sonrotoclax (Primary) ; Zanubrutinib
- Indications Chronic lymphocytic leukaemia
- Focus Adverse reactions
- Sponsors BeOne Medicines
Most Recent Events
- 03 Feb 2025 Status changed from not yet recruiting to recruiting.
- 15 Jan 2025 Planned initiation date changed from 15 Dec 2024 to 31 Jan 2025.
- 25 Nov 2024 New trial record